1. Home
  2. PRSO vs PMCB Comparison

PRSO vs PMCB Comparison

Compare PRSO & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Peraso Inc.

PRSO

Peraso Inc.

HOLD

Current Price

$1.06

Market Cap

7.8M

Sector

Technology

ML Signal

HOLD

Logo PharmaCyte  Biotech Inc.

PMCB

PharmaCyte Biotech Inc.

HOLD

Current Price

$0.75

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRSO
PMCB
Founded
2008
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8M
8.3M
IPO Year
2000
2001

Fundamental Metrics

Financial Performance
Metric
PRSO
PMCB
Price
$1.06
$0.75
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
549.9K
158.3K
Earning Date
05-11-2026
03-17-2026
Dividend Yield
N/A
N/A
EPS Growth
81.23
277.22
EPS
N/A
N/A
Revenue
$14,573,000.00
N/A
Revenue This Year
$18.48
N/A
Revenue Next Year
$53.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.99
N/A
52 Week Low
$0.75
$0.63
52 Week High
$2.37
$1.51

Technical Indicators

Market Signals
Indicator
PRSO
PMCB
Relative Strength Index (RSI) 49.91 54.72
Support Level $0.81 $0.65
Resistance Level $1.05 $0.77
Average True Range (ATR) 0.06 0.06
MACD 0.00 0.01
Stochastic Oscillator 68.33 70.88

Price Performance

Historical Comparison
PRSO
PMCB

About PRSO Peraso Inc.

Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.

About PMCB PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Share on Social Networks: